JP2020517740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517740A5 JP2020517740A5 JP2020507722A JP2020507722A JP2020517740A5 JP 2020517740 A5 JP2020517740 A5 JP 2020517740A5 JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020517740 A5 JP2020517740 A5 JP 2020517740A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- pharmaceutical composition
- domain
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023065903A JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901462A AU2017901462A0 (en) | 2017-04-21 | Agents for treating or preventing motor neurone disease and uses therefor | |
| AU2017901462 | 2017-04-21 | ||
| AU2018900762 | 2018-03-08 | ||
| AU2018900762A AU2018900762A0 (en) | 2018-03-08 | “agents for treating disease and uses therefor” | |
| PCT/AU2018/050357 WO2018191786A1 (en) | 2017-04-21 | 2018-04-20 | Cd 14 antagonist antibodies for treating neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065903A Division JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517740A JP2020517740A (ja) | 2020-06-18 |
| JP2020517740A5 true JP2020517740A5 (enExample) | 2021-05-27 |
Family
ID=63855469
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507722A Pending JP2020517740A (ja) | 2017-04-21 | 2018-04-20 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
| JP2023065903A Pending JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065903A Pending JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200148780A1 (enExample) |
| EP (1) | EP3612566A4 (enExample) |
| JP (2) | JP2020517740A (enExample) |
| KR (1) | KR20200015477A (enExample) |
| CN (1) | CN110831975A (enExample) |
| AU (1) | AU2018255489B2 (enExample) |
| IL (2) | IL270097B2 (enExample) |
| WO (1) | WO2018191786A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217916A1 (en) * | 2018-05-10 | 2019-11-14 | The Methodist Hospital | Methods for prognosis and management of disease |
| RS64034B1 (sr) | 2018-07-13 | 2023-04-28 | Alector Llc | Anti-sortilin antitela i načini njihove upotrebe |
| KR102919581B1 (ko) * | 2019-06-11 | 2026-01-30 | 알렉터 엘엘씨 | 치료요법에 사용하기 위한 항-소르틸린 항체 |
| US20220249610A1 (en) * | 2019-07-25 | 2022-08-11 | Implicit Bioscience Limited | Methods and agents for treating acute neuroinflammatory injury |
| CA3167214A1 (en) * | 2020-02-13 | 2021-08-19 | Michal Geva | Combination therapy for treating amyotrophic lateral using pridopidine and another active agent |
| EP4092051A4 (en) * | 2020-06-18 | 2023-09-06 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd | SOLUBLE ANTI-SUBTYPE CD14 ANTIBODY, KIT AND CORRESPONDING USE |
| WO2022073072A1 (en) * | 2020-10-07 | 2022-04-14 | Implicit Bioscience Limited | Methods and agents for the treatment of ocular disease |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| CN117031014A (zh) * | 2023-08-14 | 2023-11-10 | 陕西脉元生物科技有限公司 | 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN118290585B (zh) * | 2024-06-04 | 2024-08-30 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd14工程抗体及应用 |
| CN120399098B (zh) * | 2025-07-03 | 2025-09-16 | 上海玄言生物科技有限公司 | 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0485430B1 (en) * | 1989-08-01 | 1998-09-16 | The Scripps Research Institute | Methods and compositions for ameliorating the symptoms of sepsis |
| CA2163976C (en) | 1993-05-28 | 2010-06-29 | Didier J. Leturcq | Methods and compositions for inhibiting cd14 mediated cell activation |
| CA2200054C (en) * | 1994-09-16 | 2010-03-16 | The Scripps Research Institute | Use of antibodies to block the effects of gram-positive bacteria and mycobacteria |
| AU2001290315A1 (en) | 2000-11-22 | 2002-06-03 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| CA2590284A1 (en) * | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| US20090181008A1 (en) * | 2005-11-10 | 2009-07-16 | Satoris, Inc. | Methods of treating alzheimer's disease |
| KR101256837B1 (ko) * | 2009-03-09 | 2013-04-22 | 경북대학교 산학협력단 | 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도 |
| NO2539366T3 (enExample) * | 2010-02-26 | 2018-04-07 | ||
| WO2018165720A1 (en) * | 2017-03-17 | 2018-09-20 | Implicit Bioscience Pty Ltd | Agents for treating or preventing viral infections and uses therefor |
| WO2019217916A1 (en) * | 2018-05-10 | 2019-11-14 | The Methodist Hospital | Methods for prognosis and management of disease |
-
2018
- 2018-04-20 WO PCT/AU2018/050357 patent/WO2018191786A1/en not_active Ceased
- 2018-04-20 JP JP2020507722A patent/JP2020517740A/ja active Pending
- 2018-04-20 CN CN201880040765.4A patent/CN110831975A/zh active Pending
- 2018-04-20 IL IL270097A patent/IL270097B2/en unknown
- 2018-04-20 US US16/606,727 patent/US20200148780A1/en not_active Abandoned
- 2018-04-20 AU AU2018255489A patent/AU2018255489B2/en active Active
- 2018-04-20 KR KR1020197033198A patent/KR20200015477A/ko not_active Ceased
- 2018-04-20 EP EP18788123.0A patent/EP3612566A4/en active Pending
- 2018-04-20 IL IL309046A patent/IL309046B2/en unknown
-
2021
- 2021-09-23 US US17/483,517 patent/US12297287B2/en active Active
-
2023
- 2023-04-13 JP JP2023065903A patent/JP2023090751A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517740A5 (enExample) | ||
| JP2016513682A5 (enExample) | ||
| HRP20200241T1 (hr) | Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti | |
| JP2019522961A5 (enExample) | ||
| JP2020513791A5 (enExample) | ||
| KR101649168B1 (ko) | 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도 | |
| JP2020517249A5 (enExample) | ||
| JP2013500941A5 (enExample) | ||
| JP2017113028A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| JP2015530971A5 (enExample) | ||
| JP2020536888A5 (enExample) | ||
| JP2019054802A5 (enExample) | ||
| JP2016508496A5 (enExample) | ||
| JP2019110906A5 (enExample) | ||
| JP2019527194A5 (enExample) | ||
| JP2009519718A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| JP2009540018A5 (enExample) | ||
| JP2012504634A5 (enExample) | ||
| NZ585559A (en) | Humanized antibodies against tl1a | |
| JP2016527225A5 (enExample) | ||
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
| JP2016136963A5 (enExample) |